Results 31 to 40 of about 25,234 (166)

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
doaj   +1 more source

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

Diabetology & Metabolic Syndrome, 2020
Background We compared the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease (CKD) classified by degree of albuminuria.
Akinobu Nakamura, Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Yoshio Kurihara   +4 more
doaj   +1 more source

CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS [PDF]

Archiv Euromedica
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels.
Karol Wielgus, Maria Pawłowska, Piotr Bator, Adrian Bobrzyk, Angelika Wawryszuk, Weronika Kamińska, Karol Magiera, Jan Ramian, Grzegorz Łyko, Maria Antos   +9 more
openaire   +1 more source

SGLT2 Inhibitors for Nephrologists

EMJ Nephrology, 2022
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides. Sodium-glucose co-transporter-2 inhibitors are a relatively new class of oral antidiabetic drugs.
Mufti Baleegh-ur-Raheem Mahmood, Sidra Farishta   +1 more
openaire   +2 more sources

Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure

Therapeutic Advances in Cardiovascular Disease, 2019
Background: It is known that once heart failure occurs in older patients with diabetes, the overall prognosis is extremely poor. We investigated whether early initiation of SGLT2 inhibitor therapy after admission was beneficial for diabetic patients ...
Takahiro Kambara, Rei Shibata, Hiroyuki Osanai, Yoshihito Nakashima, Hiroshi Asano, Toyoaki Murohara, Masayoshi Ajioka   +6 more
doaj   +1 more source

SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report

Kidney Medicine, 2020
Euglycemic diabetic ketoacidosis is a rare but serious adverse effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors. We present a case of a woman in her 40s with type 2 diabetes mellitus hospitalized for revascularization for moyamoya disease who ...
Katherine M. Wang, Robert T. Isom
doaj   +1 more source

Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

Journal of Primary Care & Community Health
Introduction: There remains an unmet need to reduce kidney and cardiovascular risk in patients with chronic kidney disease (CKD). This report is therefore intended to provide real-world clinical guidance to primary care providers on sodium-glucose co ...
Anjay Rastogi, Ashté Collins, Ellie Kelepouris, Wayne Kotzker, John P. Middleton, Minesh Rajpal, Prabir Roy-Chaudhury, Glenn M. Chertow   +7 more
doaj   +1 more source

Is GFR decline induced by SGLT2 inhibitor of clinical importance?

Cardiovascular Diabetology
Background Use of sodium-glucose-cotransporter-2 (SGLT2) inhibitors often causes an initial decline in glomerular filtration rate (GFR). This study addresses the question whether the initial decline of renal function with SGLT2 inhibitor treatment is ...
Merve Günes-Altan, Agnes Bosch, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E. Schmieder, Dennis Kannenkeril   +6 more
doaj   +1 more source

Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.

PLoS ONE, 2017
In the Guidance for Industry from the Food and Drug Administration in 2008, excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however, relatively few studies have focused on cardiovascular safety with antidiabetic ...
Gyeongsil Lee, Seung-Won Oh, Seung-Sik Hwang, Ji Won Yoon, Sungchan Kang, Hee-Kyung Joh, Hyuktae Kwon, Jeehyun Kim, Danbee Park   +8 more
doaj   +1 more source

SGLT2 inhibitors in cardiovascular medicine [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Varzideh, Fahimeh, Kansakar, Urna, Santulli, Gaetano   +2 more
openaire   +3 more sources